Allstate president John Dugenske sells $8.89m in company stock By Investing.com

John E. Dugenske, President, Investments & Corporate Strategy at The Allstate Corporation (), sold company common stock totaling approximately $8.89 million on August 7, 2026.

The transactions involved the disposal of 32,996 shares of common stock across three separate sales. The prices for these shares ranged between $268.803 and $272.05 per share.

Specifically, Mr. Dugenske sold 3,378 shares at a weighted average price of $270.198, with individual sale prices ranging from $270.050 to $270.460. An additional 3,901 shares were sold at a weighted average price of $272.05, where actual prices varied from $271.570 to $272.090. The largest block of shares sold consisted of 25,717 shares at a weighted average price of $268.803, with individual prices for these shares ranging from $268.370 to $269.165.The insider sale comes as Allstate stock trades at $261.41, showing strong momentum with a 27% gain over the past six months and a similar year-to-date return of nearly 27%. According to InvestingPro analysis, the stock appears undervalued relative to its Fair Value, placing it among opportunities on the most undervalued stocks list. For deeper insights into Allstate’s valuation and performance metrics, investors can access the comprehensive Pro Research Report, available for this and 1,400+ other US equities.

Following these reported transactions, Mr. Dugenske directly holds 13,054 shares of Allstate common stock. He also indirectly owns 341 shares through a 401(k) Plan.

In other recent news, Allstate reported impressive second-quarter 2026 results, surpassing Wall Street’s expectations. The company achieved adjusted earnings of $8.99 per share on revenue of $18.6 billion, significantly exceeding the anticipated $5.27 per share and $15.46 billion in sales. This performance was attributed to higher premiums, stronger investment income, and improved underwriting. Following these results, Freedom Broker upgraded Allstate’s stock rating to “Buy” from “Hold,” citing the substantial earnings per share growth that outpaced market expectations.

Conversely, Wells Fargo downgraded Allstate’s stock to “Underweight” from “Equal Weight,” pointing to slowing growth and margin compression despite the strong quarterly performance. The firm adjusted its price target to $250, reflecting a potential downside from current levels. These developments highlight differing analyst perspectives on Allstate’s future trajectory, with Freedom Broker expressing optimism and Wells Fargo adopting a more cautious stance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.